IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval
Goldman Sachs upped its price target on Ionis to $75 and maintained a ‘Neutral’ rating on the shares. The U.S. Food and Drug Administration (FDA) approved Tryngolza on Wednesday as the first and only treatment indicated to reduce both triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. Ionis plans to launch … Read more